1. Home
  2. ARTW vs BCDA Comparison

ARTW vs BCDA Comparison

Compare ARTW & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Art's-Way Manufacturing Co. Inc.

ARTW

Art's-Way Manufacturing Co. Inc.

HOLD

Current Price

$2.20

Market Cap

11.9M

Sector

Industrials

ML Signal

HOLD

BCDA

BioCardia Inc.

HOLD

Current Price

$1.28

Market Cap

14.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARTW
BCDA
Founded
1956
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.9M
14.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ARTW
BCDA
Price
$2.20
$1.28
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
25.6K
72.3K
Earning Date
02-10-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.49
N/A
Revenue
$24,079,949.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$5.69
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.43
$1.00
52 Week High
$4.71
$3.20

Technical Indicators

Market Signals
Indicator
ARTW
BCDA
Relative Strength Index (RSI) 41.21 42.47
Support Level $2.18 $1.23
Resistance Level $2.28 $1.38
Average True Range (ATR) 0.13 0.09
MACD -0.01 -0.02
Stochastic Oscillator 2.70 21.43

Price Performance

Historical Comparison
ARTW
BCDA

About ARTW Art's-Way Manufacturing Co. Inc.

Art's-Way Manufacturing Co Inc is a manufacturer of agricultural equipment. It has two reportable segments: Agricultural Products, and Modular Buildings. The Agricultural Products segment fabricates and sells farming products as well as related equipment and replacement parts for these products in the United States and world wide. Its Modular Buildings segment manufactures and installs modular buildings for animal containment and various laboratory uses. It derives revenues from the Agricultural Products segment.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: